Medicine:Mood disorder

From HandWiki
Short description: Group of conditions characterised by a disturbance in mood
Mood disorder
Other namesAffective disorder
A depressive man standing by a country pond in the pouring r Wellcome V0011388.jpg
A depressive man standing by a country pond in the pouring rain
TypesBipolar disorder, cyclothymia, disruptive mood dysregulation disorder, dysthymia, major depressive disorder, premenstrual dysphoric disorder, seasonal affective disorder
MedicationAntidepressants, mood stabilizers

Mood disorder, also known as mood affective disorders, is a group of conditions of mental and behavioral disorder[1] where a disturbance in the person's mood is the main underlying feature.[2] The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).

Mood disorders fall into seven [1] groups, including; abnormally elevated mood, such as mania or hypomania; depressed mood, of which the best-known and most researched is major depressive disorder (MDD) (alternatively known as clinical depression, unipolar depression, or major depression); and moods which cycle between mania and depression, known as bipolar disorder (BD) (formerly known as manic depression). There are several sub-types of depressive disorders or psychiatric syndromes featuring less severe symptoms such as dysthymic disorder (similar to but milder than MDD) and cyclothymic disorder (similar to but milder than BD).[3][page needed] Mood disorders may also be substance induced or occur in response to a medical condition.

English psychiatrist Henry Maudsley proposed an overarching category of affective disorder.[4] The term was then replaced by mood-disorder, as the latter term refers to the underlying or longitudinal emotional state,[5] whereas the former refers to the external expression observed by others.[2]


Depressive disorders

  • Major depressive disorder (MDD), commonly called major depression, unipolar depression, or clinical depression, wherein a person has one or more major depressive episodes. After a single episode, Major Depressive Disorder (single episode) would be diagnosed. After more than one episode, the diagnosis becomes Major Depressive Disorder (Recurrent). Depression without periods of mania is sometimes referred to as unipolar depression because the mood remains at the bottom "pole" and does not climb to the higher, manic "pole" as in bipolar disorder.[6]
Individuals with a major depressive episode or major depressive disorder are at increased risk for suicide. Seeking help and treatment from a health professional dramatically reduces the individual's risk for suicide. Studies have demonstrated that asking if a depressed friend or family member has thought of committing suicide is an effective way of identifying those at risk, and it does not "plant" the idea or increase an individual's risk for suicide in any way.[7] Epidemiological studies carried out in Europe suggest that, at this moment, roughly 8.5 percent of the world's population have a depressive disorder. No age group seems to be exempt from depression, and studies have found that depression appears in infants as young as 6 months old who have been separated from their mothers.[8]
  • Depressive disorder is frequent in primary care and general hospital practice but is often undetected. Unrecognized depressive disorder may slow recovery and worsen prognosis in physical illness, therefore it is important that all doctors be able to recognize the condition, treat the less severe cases, and identify those requiring specialist care.[9]
Diagnosticians recognize several subtypes or course specifiers:
  • Atypical depression (AD) is characterized by mood reactivity (paradoxical anhedonia) and positivity,[clarification needed] significant weight gain or increased appetite ("comfort eating"), excessive sleep or somnolence (hypersomnia), a sensation of heaviness in limbs known as leaden paralysis, and significant social impairment as a consequence of hypersensitivity to perceived interpersonal rejection.[10] Difficulties in measuring this subtype have led to questions of its validity and prevalence.[11]
  • Psychotic major depression (PMD), or simply psychotic depression, is the term for a major depressive episode, in particular of melancholic nature, wherein the patient experiences psychotic symptoms such as delusions or, less commonly, hallucinations. These are most commonly mood-congruent (content coincident with depressive themes).[13]
  • Catatonic depression is a rare and severe form of major depression involving disturbances of motor behavior and other symptoms. Here, the person is mute and almost stuporose, and either is immobile or exhibits purposeless or even bizarre movements. Catatonic symptoms can also occur in schizophrenia or a manic episode, or can be due to neuroleptic malignant syndrome.[14]
  • Postpartum depression (PPD) is listed as a course specifier in DSM-IV-TR; it refers to the intense, sustained and sometimes disabling depression experienced by women after giving birth. Postpartum depression, which affects 10–15% of women, typically sets in within three months of labor, and lasts as long as three months.[15] It is quite common for women to experience a short-term feeling of tiredness and sadness in the first few weeks after giving birth; however, postpartum depression is different because it can cause significant hardship and impaired functioning at home, work, or school as well as, possibly, difficulty in relationships with family members, spouses, or friends, or even problems bonding with the newborn.[16] In the treatment of postpartum major depressive disorders and other unipolar depressions in women who are breastfeeding, nortriptyline, paroxetine (Paxil), and sertraline (Zoloft) are in general considered to be the preferred medications.[17] Women with personal or family histories of mood disorders are at particularly high risk of developing postpartum depression.[18]
  • Premenstrual dysphoric disorder (PMDD) is a severe and disabling form of premenstrual syndrome affecting 3–8% of menstruating women.[19] The disorder consists of a "cluster of affective, behavioral and somatic symptoms" that recur monthly during the luteal phase of the menstrual cycle.[19] PMDD was added to the list of depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders in 2013. The exact pathogenesis of the disorder is still unclear and is an active research topic. Treatment of PMDD relies largely on antidepressants that modulate serotonin levels in the brain via serotonin reuptake inhibitors as well as ovulation suppression using contraception.[19][20]
  • Seasonal affective disorder (SAD), also known as "winter depression" or "winter blues", is a specifier. Some people have a seasonal pattern, with depressive episodes coming on in the autumn or winter, and resolving in spring. The diagnosis is made if at least two episodes have occurred in colder months with none at other times over a two-year period or longer.[21] It is commonly hypothesised that people who live at higher latitudes tend to have less sunlight exposure in the winter and therefore experience higher rates of SAD, but the epidemiological support for this proposition is not strong (and latitude is not the only determinant of the amount of sunlight reaching the eyes in winter). It is said that this disorder can be treated by light therapy.[22] SAD is also more prevalent in people who are younger and typically affects more females than males.[23]
  • Dysthymia is a condition related to unipolar depression, where the same physical and cognitive problems are evident, but they are not as severe and tend to last longer (usually at least 2 years).[24] The treatment of dysthymia is largely the same as for major depression, including antidepressant medications and psychotherapy.[25]
  • Double depression can be defined as a fairly depressed mood (dysthymia) that lasts for at least two years and is punctuated by periods of major depression.[24]
  • Depressive Disorder Not Otherwise Specified (DD-NOS) is designated by the code 311 for depressive disorders that are impairing but do not fit any of the officially specified diagnoses. According to the DSM-IV, DD-NOS encompasses "any depressive disorder that does not meet the criteria for a specific disorder." It includes the research diagnoses of recurrent brief depression, and minor depressive disorder listed below.
  • Depressive personality disorder (DPD) is a controversial psychiatric diagnosis that denotes a personality disorder with depressive features. Originally included in the DSM-II, depressive personality disorder was removed from the DSM-III and DSM-III-R.[26] Recently, it has been reconsidered for reinstatement as a diagnosis. Depressive personality disorder is currently described in Appendix B in the DSM-IV-TR as worthy of further study.
  • Recurrent brief depression (RBD), distinguished from major depressive disorder primarily by differences in duration. People with RBD have depressive episodes about once per month, with individual episodes lasting less than two weeks and typically less than 2–3 days. Diagnosis of RBD requires that the episodes occur over the span of at least one year and, in female patients, independently of the menstrual cycle.[27] People with clinical depression can develop RBD, and vice versa, and both illnesses have similar risks.[28][clarification needed]
  • Minor depressive disorder, or simply minor depression, which refers to a depression that does not meet full criteria for major depression but in which at least two symptoms are present for two weeks.[29]

Bipolar disorders

  • Bipolar disorder (BD) (also called "manic depression" or "manic-depressive disorder"), an unstable emotional condition characterized by cycles of abnormal, persistent high mood (mania) and low mood (depression),[30] which was formerly known as "manic depression" (and in some cases rapid cycling, mixed states, and psychotic symptoms).[31] Subtypes include:
  • Bipolar I is distinguished by the presence or history of one or more manic episodes or mixed episodes with or without major depressive episodes. A depressive episode is not required for the diagnosis of Bipolar I Disorder, but depressive episodes are usually part of the course of the illness.
  • Bipolar II consisting of recurrent intermittent hypomanic and depressive episodes or mixed episodes.
  • Cyclothymia is a form of bipolar disorder, consisting of recurrent hypomanic and dysthymic episodes, but no full manic episodes or full major depressive episodes.
  • Bipolar disorder not otherwise specified (BD-NOS), sometimes called "sub-threshold" bipolar, indicates that the patient has some symptoms in the bipolar spectrum (e.g., manic and depressive symptoms) but does not fully qualify for any of the three formal bipolar DSM-IV diagnoses mentioned above.
It is estimated that roughly 1% of the adult population has bipolar I, a further 1% has bipolar II or cyclothymia, and somewhere between 2% and 5% percent have "sub-threshold" forms of bipolar disorder. Furthermore, the possibility of getting bipolar disorder when one parent is diagnosed with it is 15–30%. Risk, when both parents have it, is 50–75%. Also, while with bipolar siblings the risk is 15–25%, with identical twins it is about 70%.[32]

A minority of people with bipolar disorder have high creativity, artistry or a particular gifted talent. Before the mania phase becomes too extreme, its energy, ambition, enthusiasm and grandiosity often bring people with this type of mood disorder life's masterpieces.[30]


A mood disorder can be classified as substance-induced if its etiology can be traced to the direct physiologic effects of a psychoactive drug or other chemical substance, or if the development of the mood disorder occurred contemporaneously with substance intoxication or withdrawal. Also, an individual may have a mood disorder coexisting with a substance abuse disorder. Substance-induced mood disorders can have features of a manic, hypomanic, mixed, or depressive episode. Most substances can induce a variety of mood disorders. For example, stimulants such as amphetamine, methamphetamine, and cocaine can cause manic, hypomanic, mixed, and depressive episodes.[33]


High rates of major depressive disorder occur in heavy drinkers and those with alcoholism. Controversy has previously surrounded whether those who abused alcohol and developed depression were self-medicating their pre-existing depression. But recent research has concluded that, while this may be true in some cases, alcohol misuse directly causes the development of depression in a significant number of heavy drinkers. Participants studied were also assessed during stressful events in their lives and measured on a Feeling Bad Scale. Likewise, they were also assessed on their affiliation with deviant peers, unemployment, and their partner's substance use and criminal offending.[34][35][36] High rates of suicide also occur in those who have alcohol-related problems.[37] It is usually possible to differentiate between alcohol-related depression and depression that is not related to alcohol intake by taking a careful history of the patient.[36][38][39] Depression and other mental health problems associated with alcohol misuse may be due to distortion of brain chemistry, as they tend to improve on their own after a period of abstinence.[40]


Benzodiazepines, such as alprazolam, clonazepam, lorazepam and diazepam, can cause both depression and mania.[41]

Benzodiazepines are a class of medication commonly used to treat anxiety, panic attacks and insomnia, and are also commonly misused and abused. Those with anxiety, panic and sleep problems commonly have negative emotions and thoughts, depression, suicidal ideations, and often have comorbid depressive disorders. While the anxiolytic and hypnotic effects of benzodiazepines disappear as tolerance develops, depression and impulsivity with high suicidal risk commonly persist.[42] These symptoms are "often interpreted as an exacerbation or as a natural evolution of previous disorders and the chronic use of sedatives is overlooked".[42] Benzodiazepines do not prevent the development of depression, can exacerbate preexisting depression, can cause depression in those with no history of it, and can lead to suicide attempts.[42][43][44][45][46] Risk factors for attempted and completed suicide while using benzodiazepines include high dose prescriptions (even in those not misusing the medications), benzodiazepine intoxication, and underlying depression.[41][47][48]

The long-term use of benzodiazepines may have a similar effect on the brain as alcohol, and are also implicated in depression.[49] As with alcohol, the effects of benzodiazepine on neurochemistry, such as decreased levels of serotonin and norepinephrine, are believed to be responsible for the increased depression.[50][51][52][53][54][55] Additionally, benzodiazepines can indirectly worsen mood by worsening sleep (i.e., benzodiazepine-induced sleep disorder). Like alcohol, benzodiazepines can put people to sleep but, while asleep, they disrupt sleep architecture: decreasing sleep time, delaying time to REM sleep, and decreasing deep sleep (the most restorative part of sleep for both energy and mood).[56][57][58] Just as some antidepressants can cause or worsen anxiety in some patients due to being activating, benzodiazepines can cause or worsen depression due to being a central nervous system depressant—worsening thinking, concentration and problem solving (i.e., benzodiazepine-induced neurocognitive disorder).[41] However, unlike antidepressants, in which the activating effects usually improve with continued treatment, benzodiazepine-induced depression is unlikely to improve until after stopping the medication.

In a long-term follow-up study of patients dependent on benzodiazepines, it was found that 10 people (20%) had taken drug overdoses while on chronic benzodiazepine medication despite only two people ever having had any pre-existing depressive disorder. A year after a gradual withdrawal program, no patients had taken any further overdoses.[59]

Just as with intoxication and chronic use, benzodiazepine withdrawal can also cause depression.[60][61][62] While benzodiazepine-induced depressive disorder may be exacerbated immediately after discontinuation of benzodiazepines, evidence suggests that mood significantly improves after the acute withdrawal period to levels better than during use.[42] Depression resulting from withdrawal from benzodiazepines usually subsides after a few months but in some cases may persist for 6–12 months.[63][64]

Due to another medical condition

"Mood disorder due to a general medical condition" is used to describe manic or depressive episodes which occur secondary to a medical condition.[65] There are many medical conditions that can trigger mood episodes, including neurological disorders (e.g. dementias), metabolic disorders (e.g. electrolyte disturbances), gastrointestinal diseases (e.g. cirrhosis), endocrine disease (e.g. thyroid abnormalities), cardiovascular disease (e.g. heart attack), pulmonary disease (e.g. chronic obstructive pulmonary disease), cancer, and autoimmune diseases (e.g. multiple sclerosis).[65]

Not otherwise specified

Mood disorder not otherwise specified (MD-NOS) is a mood disorder that is impairing but does not fit in with any of the other officially specified diagnoses. In the DSM-IV MD-NOS is described as "any mood disorder that does not meet the criteria for a specific disorder."[66] MD-NOS is not used as a clinical description but as a statistical concept for filing purposes.[67]

Most cases of MD-NOS represent hybrids between mood and anxiety disorders, such as mixed anxiety-depressive disorder or atypical depression.[67] An example of an instance of MD-NOS is being in minor depression frequently during various intervals, such as once every month or once in three days.[66] There is a risk for MD-NOS not to get noticed, and for that reason not to get treated.[68]


Meta-analyses show that high scores on the personality domain neuroticism are a strong predictor for the development of mood disorders.[69] A number of authors have also suggested that mood disorders are an evolutionary adaptation (see also evolutionary psychiatry).[70] A low or depressed mood can increase an individual's ability to cope with situations in which the effort to pursue a major goal could result in danger, loss, or wasted effort.[71] In such situations, low motivation may give an advantage by inhibiting certain actions. This theory helps to explain why negative life incidents precede depression in around 80 percent of cases,[72][73] and why they so often strike people during their peak reproductive years. These characteristics would be difficult to understand if depression were a dysfunction.[71]

A depressed mood is a predictable response to certain types of life occurrences, such as loss of status, divorce, or death of a child or spouse. These are events that signal a loss of reproductive ability or potential, or that did so in humans' ancestral environment. A depressed mood can be seen as an adaptive response, in the sense that it causes an individual to turn away from the earlier (and reproductively unsuccessful) modes of behavior.

A depressed mood is common during illnesses, such as influenza. It has been argued that this is an evolved mechanism that assists the individual in recovering by limiting his/her physical activity.[74] The occurrence of low-level depression during the winter months, or seasonal affective disorder, may have been adaptive in the past, by limiting physical activity at times when food was scarce.[74] It is argued that humans have retained the instinct to experience low mood during the winter months, even if the availability of food is no longer determined by the weather.[74]

Much of what is known about the genetic influence of clinical depression is based upon research that has been done with identical twins. Identical twins have exactly the same genetic code. It has been found that when one identical twin becomes depressed the other will also develop clinical depression approximately 76% of the time. When identical twins are raised apart from each other, they will both become depressed about 67% of the time. Because both twins become depressed at such a high rate, the implication is that there is a strong genetic influence. If it happened that when one twin becomes clinically depressed the other always develops depression, then clinical depression would likely be entirely genetic.[75]

Bipolar disorder is also considered a mood disorder and it is hypothesized that it might be caused by mitochondrial dysfunction.[76][77][78]

Sex Differences Mood disorders, specifically stress-related mood disorders such as anxiety and depression, have been shown to have differing rates of diagnosis based on sex. In the United States, women are two times more likely than men to be diagnosed with a stress-related mood disorder.[79][80] Underlying these sex differences, studies have shown a dysregulation of stress-responsive neuroendocrine function causing an increase in the likelihood of developing these affective disorders.[81] Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis could provide potential insight into how these sex differences arise. Neuropeptide corticotropin-releasing factor (CRF) is released from the paraventricular nucleus (PVN) of the hypothalamus, stimulating adrenocorticotropic hormone (ACTH) release into the blood stream. From here ACTH triggers the release of glucocorticoids such as cortisol from the adrenal cortex. Cortisol, known as the main stress hormone, creates a negative feedback loop back to the hypothalamus to deactivate the stress response.[82] When a constant stressor is present, the HPA axis remains overactivated and cortisol is constantly produced. This chronic stress is associated with sustained CRF release, resulting in the increased production of anxiety- and depressive-like behaviors and serving as a potential mechanism for differences in prevalence between men and women.[79]



The DSM-5, released in May 2013, separates the mood disorder chapter from the DSM-TR-IV into two sections: Depressive and related disorders and bipolar and related disorders. Bipolar disorders falls in between depressive disorders and schizophrenia spectrum and related disorders "in recognition of their place as a bridge between the two diagnostic classes in terms of symptomatology, family history and genetics" (Ref. 1, p 123).[83] Bipolar disorders underwent a few changes in the DSM-5, most notably the addition of more specific symptomology related to hypomanic and mixed manic states. Depressive disorders underwent the most changes, the addition of three new disorders: disruptive mood dysregulation disorder, persistent depressive disorder (previously dysthymia), and premenstrual dysphoric disorder (previously in appendix B, the section for disorders needing further research). Disruptive mood dysregulation disorder is meant as a diagnosis for children and adolescents who would normally be diagnosed with bipolar disorder as a way to limit the bipolar diagnosis in this age cohort. Major depressive disorder (MDD) also underwent a notable change, in that the bereavement clause has been removed. Those previously exempt from a diagnosis of MDD due to bereavement are now candidates for the MDD diagnosis.[84]


There are different types of treatments available for mood disorders, such as therapy and medications. Behaviour therapy, cognitive behaviour therapy and interpersonal therapy have all shown to be potentially beneficial in depression.[85][86] Major depressive disorder medications usually include antidepressants; a combination of antidepressants and cognitive behavioral therapy has shown to be more effective than one treatment alone.[87] Bipolar disorder medications can consist of antipsychotics, mood stabilizers, anticonvulsants[88] and/or lithium. Lithium specifically has been proven to reduce suicide and all causes of mortality in people with mood disorders.[89] If mitochondrial dysfunction or mitochondrial diseases are the cause of mood disorders like bipolar disorder,[76] then it has been hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options.[90] In determining treatment, there are many types of depression scales that are used. One of the depression scales is a self-report scale called Beck Depression Inventory (BDI). Another scale is the Hamilton Depression Rating Scale (HAMD). HAMD is a clinical rating scale in which the patient is rated based on clinician observation.[91] The Center for Epidemiologic Studies Depression Scale (CES-D) is a scale for depression symptoms that applies to the general population. This scale is typically used in research and not for self-reports. The PHQ-9 which stands for Patient-Health Questionnaire-9 questions, is a self-report as well. Finally, the Mood Disorder Questionnaire (MDQ) evaluates bipolar disorder.[92]


According to a substantial number of epidemiology studies conducted, women are twice as likely to develop certain mood disorders, such as major depression. Although there is an equal number of men and women diagnosed with bipolar II disorder, women have a slightly higher frequency of the disorder.[93]

The prevalence of depressive symptoms has increased over the years with recent generations reporting a 6% increase in symptoms of depression compared to individuals from older generations.[94]

In 2011, mood disorders were the most common reason for hospitalization among children aged 1–17 years in the United States, with approximately 112,000 stays.[95] Mood disorders were top principal diagnosis for Medicaid super-utilizers in the United States in 2012.[96] Further, a study of 18 States found that mood disorders accounted for the highest number of hospital readmissions among Medicaid patients and the uninsured, with 41,600 Medicaid patients and 12,200 uninsured patients being readmitted within 30 days of their index stay—a readmission rate of 19.8 per 100 admissions and 12.7 per 100 admissions, respectively.[97] In 2012, mood and other behavioral health disorders were the most common diagnoses for Medicaid-covered and uninsured hospital stays in the United States (6.1% of Medicaid stays and 5.2% of uninsured stays).[98]

A study conducted in 1988 to 1994 amongst young American adults involved a selection of demographic and health characteristics. A population-based sample of 8,602 men and women ages 17–39 years participated. Lifetime prevalence were estimated based on six mood measures:

  • major depressive episode (MDE) 8.6%,
  • major depressive disorder with severity (MDE-s) 7.7%,
  • dysthymia 6.2%,
  • MDE-s with dysthymia 3.4%,
  • any bipolar disorder 1.6%, and
  • any mood disorder 11.5%.[99]


Kay Redfield Jamison and others have explored the possible links between mood disorders – especially bipolar disorder – and creativity. It has been proposed that a "ruminating personality type may contribute to both [mood disorders] and art."[100]

Jane Collingwood notes an Oregon State University study that

"looked at the occupational status of a large group of typical patients and found that 'those with bipolar illness appear to be disproportionately concentrated in the most creative occupational category.' They also found that the likelihood of 'engaging in creative activities on the job' is significantly higher for bipolar than nonbipolar workers".[101]

In Liz Paterek's article "Bipolar Disorder and the Creative Mind"[102] she wrote

"Memory and creativity are related to mania. Clinical studies have shown that those in a manic state will rhyme, find synonyms, and use alliteration more than controls. This mental fluidity could contribute to an increase in creativity. Moreover, mania creates increases in productivity and energy. Those in a manic state are more emotionally sensitive and show less inhibition about attitudes, which could create greater expression. Studies performed at Harvard looked into the amount of original thinking in solving creative tasks. Bipolar individuals, whose disorder was not severe, tended to show greater degrees of creativity".

The relationship between depression and creativity appears to be especially strong among poets.[103][104]

See also


  1. 1.0 1.1 Drs; Sartorius, Norman; Henderson, A.S.; Strotzka, H.; Lipowski, Z.; Yu-cun, Shen; You-xin, Xu; Strömgren, E.; Glatzel, J. et al.. "The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines". Microsoft Word. pp. 91–3. 
  2. 2.0 2.1 Sadock 2002, p. 534
  3. Carlson 2007
  4. Lewis, AJ (1934). "Melancholia: A Historical Review.". Journal of Mental Science 80 (328): 1–42. doi:10.1192/bjp.80.328.1. 
  5. Berrios, G E (1985). "The Psychopathology of Affectivity: Conceptual and Historical Aspects". Psychological Medicine 15 (4): 745–758. doi:10.1017/S0033291700004980. PMID 3909185. 
  6. Parker 1996, p. 173
  7. The ICD-10 Classification of Mental and Behavioural Disorders. World Health Organisation. 1993.
  8. Ayuso-Mateos J.L. (2001). "Depressive Disorders in Europe: Prevalence figures from the ODIN study". British Journal of Psychiatry 179 (4): 308–316. doi:10.1192/bjp.179.4.308. PMID 11581110. 
  9. Gelder & Mayou, Geddes (2005). Psychiatry: Page 170. New York, NY; Oxford University Press Inc.
  10. American Psychiatric Association 2000, pp. 421–22
  11. Sadock 2002, p. 548
  12. American Psychiatric Association 2000, pp. 419–20
  13. American Psychiatric Association 2000, p. 412
  14. American Psychiatric Association 2000, pp. 417–18
  15. Ruta M Nonacs. eMedicine – Postpartum Depression
  16. O'Hara, Michael W. "Postpartum Depression: Causes and consequences." 1995.
  17. "Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants". Am J Psychiatry 161 (6): 1066–78. 2004. doi:10.1176/appi.ajp.161.6.1066. PMID 15169695. 
  18. Parry, Barbara L. "Premenstrual and Postpartum Mood Disorders." Volume 9.1. 1996. pp=11–16
  19. 19.0 19.1 19.2 Rapkin, AJ; Lewis, EI (November 2013). "Treatment of premenstrual dysphoric disorder". Womens Health (Lond Engl) 9 (6): 537–56. doi:10.2217/whe.13.62. PMID 24161307. 
  20. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders : DSM-5. (5th ed.). Washington, D.C.: American Psychiatric Association. pp. 171–175. ISBN 978-0-89042-554-1. 
  21. American Psychiatric Association 2000, p. 425
  22. Rosenthal, N.E (1984). "A Description of the syndrome and preliminary findings with Light Therapy". Archives of General Psychiatry 41 (1): 72–80. doi:10.1001/archpsyc.1984.01790120076010. PMID 6581756. 
  23. Lam Raymond W.; Levitan Robert D. (2000). "Pathophysiology of seasonal affective disorder: a review". Journal of Psychiatry and Neuroscience 25 (5): 469–480. PMID 11109298. 
  24. 24.0 24.1 Schacter, Daniel L., Daniel T. Gilbert, and Daniel M. Wegner. "Chapter 14: Psychological Disorders." Psychology.; Second Edition. N.p.: Worth, Incorporated, 2010. 564–65. Print.
  25. The ICD-10 Classification of Mental and Behavioural Disorders World Health Organisation 1993
  26. Millon, T. (2006). Personality subtypes. Retrieved from "Archived copy". 
  27. American Psychiatric Association 2000, p. 778
  28. Carta, Mauro Giovanni et al. (2003). "Is recurrent brief depression an expression of mood spectrum disorders in young people?". European Archives of Psychiatry and Clinical Neuroscience 253 (3): 149–53. doi:10.1007/s00406-003-0418-5. PMID 12904979. 
  29. "A descriptive analysis of minor depression". American Journal of Psychiatry 159 (4): 637–43. 2002. doi:10.1176/appi.ajp.159.4.637. PMID 11925303. 
  30. 30.0 30.1 D. Schacter; D. Gilbert; D. Wegner (2011). Psychology 2nd Ed. Worth Publishers. pp. 570. 
  31. Melissa Conrad Stöppler, MD. "Bipolar Disorder (cont.)". MedicineNet, Inc.. 
  32. Abell, S.; Ey, J. L. (4 June 2009). "Bipolar Disorder". Clinical Pediatrics 48 (6): 693–694. doi:10.1177/0009922808316663. PMID 19498214. (registration required)
  33. "Methods for Diagnosing Mood Disorders". [unreliable source?]
  34. "Tests of causal links between alcohol abuse or dependence and major depression". Arch. Gen. Psychiatry 66 (3): 260–6. March 2009. doi:10.1001/archgenpsychiatry.2008.543. PMID 19255375. 
  35. "Age of Onset and Temporal Sequencing of Lifetime DSM-IV Alcohol Use Disorders Relative to Comorbid Mood and Anxiety Disorders". Drug Alcohol Depend 94 (1–3): 234–45. April 2008. doi:10.1016/j.drugalcdep.2007.11.022. PMID 18215474. 
  36. 36.0 36.1 "A comparison of factors associated with substance-induced versus independent depressions". J Stud Alcohol Drugs 68 (6): 805–12. November 2007. doi:10.15288/jsad.2007.68.805. PMID 17960298. 
  37. "[Attempted suicide and alcohol dependence: results of an epidemiologic survey]" (in fr). Encephale 24 (4): 347–54. 1998. PMID 9809240. 
  38. "Comparison of induced and independent major depressive disorders in 2,945 alcoholics". Am J Psychiatry 154 (7): 948–57. July 1997. doi:10.1176/ajp.154.7.948. PMID 9210745. 
  39. "The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls". Addiction 92 (10): 1289–304. October 1997. doi:10.1111/j.1360-0443.1997.tb02848.x. PMID 9489046. 
  40. "Psychopathology of alcoholics during withdrawal and early abstinence". Eur Psychiatry 15 (8): 483–8. December 2000. doi:10.1016/S0924-9338(00)00519-8. PMID 11175926. 
  41. 41.0 41.1 41.2 American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders, fifth edition. Arlington, VA: American Psychiatric Association. 
  42. 42.0 42.1 42.2 42.3 Michelini, S.; Cassano, G. B.; Frare, F.; Perugi, G. (1 July 1996). "Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders". Pharmacopsychiatry 29 (4): 127–134. doi:10.1055/s-2007-979558. ISSN 0176-3679. PMID 8858711. 
  43. Lydiard, R. B.; Brawman-Mintzer, O.; Ballenger, J. C. (1 August 1996). "Recent developments in the psychopharmacology of anxiety disorders". Journal of Consulting and Clinical Psychology 64 (4): 660–668. doi:10.1037/0022-006x.64.4.660. ISSN 0022-006X. PMID 8803355. 
  44. Baldwin, David S.; Anderson, Ian M.; Nutt, David J.; Bandelow, Borwin; Bond, A.; Davidson, Jonathan R. T.; den Boer, J. A.; Fineberg, Naomi A. et al. (1 November 2005). "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology (Oxford, England) 19 (6): 567–596. doi:10.1177/0269881105059253. ISSN 0269-8811. PMID 16272179. 
  45. Ashton, H. (1 June 1987). "Benzodiazepine withdrawal: outcome in 50 patients". British Journal of Addiction 82 (6): 665–671. doi:10.1111/j.1360-0443.1987.tb01529.x. ISSN 0952-0481. PMID 2886145. 
  46. Gelpin, E.; Bonne, O.; Peri, T.; Brandes, D.; Shalev, A. Y. (1 September 1996). "Treatment of recent trauma survivors with benzodiazepines: a prospective study". The Journal of Clinical Psychiatry 57 (9): 390–394. ISSN 0160-6689. PMID 9746445. 
  47. Hawkins, Eric J.; Malte, Carol A.; Imel, Zac E.; Saxon, Andrew J.; Kivlahan, Daniel R. (1 July 2012). "Prevalence and trends of benzodiazepine use among Veterans Affairs patients with posttraumatic stress disorder, 2003–2010". Drug and Alcohol Dependence 124 (1–2): 154–161. doi:10.1016/j.drugalcdep.2012.01.003. ISSN 1879-0046. PMID 22305658. 
  48. Pfeiffer, Paul N.; Ganoczy, Dara; Ilgen, Mark; Zivin, Kara; Valenstein, Marcia (1 January 2009). "Comorbid Anxiety as a Suicide Risk Factor Among Depressed Veterans". Depression and Anxiety 26 (8): 752–757. doi:10.1002/da.20583. ISSN 1091-4269. PMID 19544314. 
  49. Semple, David; Roger Smyth; Jonathan Burns; Rajan Darjee; Andrew McIntosh (2007). "13". Oxford Handbook of Psychiatry. United Kingdom: Oxford University Press. p. 540. ISBN 978-0-19-852783-1. 
  50. Collier, Judith; Longmore, Murray (2003). "4". in Scally, Peter. Oxford Handbook of Clinical Specialties (6 ed.). Oxford University Press. p. 366. ISBN 978-0-19-852518-9. 
  51. Professor Heather Ashton (2002). "Benzodiazepines: How They Work and How to Withdraw". 
  52. "Emergence of depressive symptoms in patients receiving alprazolam for panic disorder". Am J Psychiatry 144 (5): 664–5. May 1987. doi:10.1176/ajp.144.5.664. PMID 3578580. 
  53. "Long-term benzodiazepine use and depression". Am J Psychiatry 142 (1): 144–5. 1 January 1985. doi:10.1176/ajp.142.1.144-b. PMID 2857068. 
  54. Longo, L. P.; Johnson, B. (1 April 2000). "Addiction: Part I. Benzodiazepines—side effects, abuse risk and alternatives". American Family Physician 61 (7): 2121–2128. ISSN 0002-838X. PMID 10779253. 
  55. Psychiatry, third edition. Chichester, England: John Wiley & Sons. 2008. pp. 2603–2615. 
  56. Ashton, Heather (1 May 2005). "The diagnosis and management of benzodiazepine dependence". Current Opinion in Psychiatry 18 (3): 249–255. doi:10.1097/01.yco.0000165594.60434.84. ISSN 0951-7367. PMID 16639148. 
  57. Morin, Charles M.; Bélanger, Lynda; Bastien, Célyne; Vallières, Annie (1 January 2005). "Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse". Behaviour Research and Therapy 43 (1): 1–14. doi:10.1016/j.brat.2003.12.002. ISSN 0005-7967. PMID 15531349. 
  58. Poyares, Dalva; Guilleminault, Christian; Ohayon, Maurice M.; Tufik, Sergio (1 June 2004). "Chronic benzodiazepine usage and withdrawal in insomnia patients". Journal of Psychiatric Research 38 (3): 327–334. doi:10.1016/j.jpsychires.2003.10.003. ISSN 0022-3956. PMID 15003439. 
  59. Professor C Heather Ashton (1987). "Benzodiazepine Withdrawal: Outcome in 50 Patients". British Journal of Addiction 82: 655–671. 
  60. "Discontinuation of Alprazolam Treatment in Panic Patients". Am J Psychiatry 144 (3): 303–8. March 1987. doi:10.1176/ajp.144.3.303. PMID 3826428. Retrieved 10 December 2008. 
  61. Modell JG (March–April 1997). "Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression". Psychosomatics 38 (2): 160–1. doi:10.1016/S0033-3182(97)71493-2. PMID 9063050. Retrieved 21 March 2009. 
  62. Lader M (1994). "Anxiety or depression during withdrawal of hypnotic treatments". J Psychosom Res 38 (Suppl 1): 113–23; discussion 118–23. doi:10.1016/0022-3999(94)90142-2. PMID 7799243. 
  63. Ashton CH (March 1995). "Protracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome". Psychiatric Annals 25 (3): 174–179. doi:10.3928/0048-5713-19950301-11. 
  64. Professor Heather Ashton (2004). "Protracted Withdrawal Symptoms From Benzodiazepines". Comprehensive Handbook of Drug & Alcohol Addiction. 
  65. 65.0 65.1 Hales E and Yudofsky JA, eds, The American Psychiatric Press Textbook of Psychiatry, Washington, DC: American Psychiatric Publishing, Inc., 2003
  66. 66.0 66.1 American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. (4th ed.). 
  67. 67.0 67.1 HAGOP S. AKISKAL, M.D. (2 November 2004). "MOOD DISORDERS: CLINICAL FEATURES". Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 
  68. Williams Daniel T.; Hirsch Scott; Coffey Barbara (2007). "Mood and Anxiety Symptoms in An Adolescent with Pervasive Developmental Disorder Not Otherwise Specified and Moderate Mental Retardation". Journal of Child and Adolescent Psychopharmacology 17 (5): 721–726. doi:10.1089/cap.2007.17503. PMID 17979592. 
  69. Jeronimus (2016). "Neuroticism's prospective association with mental disorders: A meta-analysis on 59 longitudinal/prospective studies with 443 313 participants". Psychological Medicine 46 (14): 2883–2906. doi:10.1017/S0033291716001653. PMID 27523506. 
  70. Allen, N.; Badcock, P. (2006). "Darwinian models of depression: A review of evolutionary accounts of mood and mood disorders". Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (5): 815–826. doi:10.1016/j.pnpbp.2006.01.007. PMID 16647176. 
  71. 71.0 71.1 Nesse R (2000). "Is Depression an Adaptation?". Arch. Gen. Psychiatry 57 (1): 14–20. doi:10.1001/archpsyc.57.1.14. PMID 10632228. 
  72. Kessler, R (1997). "The Effects of Stressful Life Events on Depression". Annual Review of Psychology 48: 191–214. doi:10.1146/annurev.psych.48.1.191. PMID 9046559. 
  73. Nolen-Hoeksema, S (2013). Abnormal Psychology (6th ed.). McGraw-Hill Higher Education. p. 188. ISBN 9780077499693. Retrieved 5 December 2014. 
  74. 74.0 74.1 74.2 Why We Get Sick: The New Science of Darwinian Medicine, Randolphe M. Nesse and George C. Williams | Vintage Books | 1994 | ISBN:0-8129-2224-7
  75. "Archived copy". 
  76. 76.0 76.1 "Mitochondrial dysfunction and molecular pathways of disease". Experimental and Molecular Pathology 83 (1): 84–92. 2007. doi:10.1016/j.yexmp.2006.09.008. PMID 17239370. 
  77. "Mitochondrial dysfunction and bipolar disorder". 29 September 2017.  Mitochondrial dysfunction and bipolar disorder
  78. "Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications". Neurosci Biobehav Rev 68: 694–713. 2016. doi:10.1016/j.neubiorev.2016.06.040. PMID 27377693. 
  79. 79.0 79.1 Rosinger, Zachary (2020). "Sex-dependent effects of chronic variable stress on discrete corticotropin-releasing factor receptor 1 cell populations". Physiology & Behavior. 
  80. Blume, Shannon (23 August 2019). "Disruptive effects of repeated stress on basolateral amygdala neurons and fear behavior across the estrous cycle in rats". Scientific Reports. doi:10.1038/s41598-019-48683-3. 
  81. Weiser, Michael (26 July 2008). "Androgen regulation of corticotropin-releasing hormone receptor 2 (CRHR2) mRNA expression and receptor binding in the rat brain". Experimental Neurology. PMID 18706413. 
  82. Ramot, Assaf (March 2017). "Hypothalamic CRFR1 is essential for HPA axis regulation following chronic stress". Nature Neuroscience. PMID 28135239. 
  83. American Psychiatric Association (2013). Diagnostic and Statianual (5th ed.). Arlington, VA: American Psychiatric Association. 
  84. Parker, George (2014). "DSM-5 and Psychotic and Mood Disorders". Journal of the American Academy of Psychiatry and the Law 42: 182–190. PMID 24986345. 
  85. Nolen-Hoeksema, S (2013). Abnormal Psychology (6th ed.). McGraw-Hill Higher Education. p. 203. ISBN 9780077499693. Retrieved 5 December 2014. 
  86. Weston, Drew; Morrison, Kate (2001). "A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: An empirical examination of the status of empirically supported therapies". Journal of Consulting and Clinical Psychology 69 (6): 875–899. doi:10.1037/0022-006X.69.6.875. 
  87. Karyotaki, E.; Smit, Y.; Holdt Henningsen, K.; Huibers, M.J.H.; Robays, J.; de Beurs, D.; Cuijpers, P. (2016). "Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects". Journal of Affective Disorders 194: 144–152. doi:10.1016/j.jad.2016.01.036. ISSN 0165-0327. 
  88. Keck Jr., Paul E.; McElroy, Susan L.; Strakowski, Stephen M. (1998). "Anticonvulsants and antipsychotics in the treatment of bipolar disorder.". The Journal of Clinical Psychiatry 59 (Suppl 6): 74–82. PMID 9674940. 
  89. Cipriani, A (2013). "Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis". DARE 346: 1. doi:10.1136/bmj.f3646. PMID 23814104. 
  90. "Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development". Australian & New Zealand Journal of Psychiatry 47 (1): 26–42. 2012. doi:10.1177/0004867412449303. PMID 22711881. 
  91. Kim, Eun Young; Hwang, Samuel Suk-Hyun; Lee, Nam Young; Kim, Se Hyun; Lee, Hyun Jeong; Kim, Yong Sik; Ahn, Yong Min (June 2013). "Intelligence, temperament, and personality are related to over- or under-reporting of affective symptoms by patients with euthymic mood disorder". Journal of Affective Disorders 148 (2–3): 235–242. doi:10.1016/j.jad.2012.11.065. ISSN 0165-0327. PMID 23270973. 
  92. Choi, Seung W.; Schalet, Benjamin; Cook, Karon F.; Cella, David (2014). "Establishing a common metric for depressive symptoms: Linking the BDI-II, CES-D, and PHQ-9 to PROMIS Depression.". Psychological Assessment 26 (2): 513–527. doi:10.1037/a0035768. ISSN 1939-134X. PMID 24548149. 
  93. Bauer, M., Pfenning, A. (2005). Epidemiology of Bipolar Disorders. Epilepsia, 46(s4), 8–13.
  94. "Depression Millennials Increasing" (in en). 2019-03-12. 
  95. Pfuntner A., Wier L.M., Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011. HCUP Statistical Brief #162. September 2013. Agency for Healthcare Research and Quality, Rockville, MD. "Most Frequent Conditions in U.S. Hospitals, 2011 #162". 
  96. "Characteristics of Hospital Stays for Nonelderly Medicaid Super-Utilizers, 2012". HCUP Statistical Brief #184. Rockville, MD: Agency for Healthcare Research and Quality. November 2014. 
  97. "Conditions With the Largest Number of Adult Hospital Readmissions by Payer, 2011.". HCUP Statistical Brief #172. Rockville, MD: Agency for Healthcare Research and Quality. April 2014. 
  98. "Characteristics of Medicaid and Uninsured Hospitalizations, 2012". HCUP Statistical Brief #183. Rockville, MD: Agency for Healthcare Research and Quality. October 2014. 
  99. "Prevalence of mood disorders in a national sample of young American adults". Social Psychiatry and Psychiatric Epidemiology 38 (11): 618–624. 2003. doi:10.1007/s00127-003-0682-8. PMID 14614549. 
  100. "Experts ponder link between creativity, mood disorders -". CNN. 2 April 2009. 
  101. Collingwood, Jane. "The Link Between Bipolar Disorder and Creativity | Psych Central." Psych Central – Trusted Mental Health, Depression, Bipolar, ADHD and Psychology Information . Web. 19 November 2011. <"Archived copy". >.
  102. Paterek, Liz. "Bipolar Disorder and the Creative Mind." Serendip. 2006. Web. <>.
  103. Kaufman, JC (2001). "The Sylvia Plath effect: Mental illness in eminent creative writers". Journal of Creative Behavior 35 (1): 37–50. doi:10.1002/j.2162-6057.2001.tb01220.x. ISSN 0022-0175. 
  104. Bailey, DS (2003). "Considering Creativity: The 'Sylvia Plath' effect". Monitor on Psychology 34 (10): 42. 
Cited texts

External links